Announced Tue, 11 Aug · 15:39 IST
Varenyam Bio capex doubled to Rs 300 cr; adds biologics CDMO capability
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-0.0%1-day move
₹1375.30
prior close
—
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————-0.0-2.3————————
Up moveDown movePending
AI summary
Bharat Parenterals' wholly owned subsidiary Varenyam Biolifesciences is upgrading its Savli facility to add biologics and biosimilar CDMO services alongside its existing oncology line. Phase 1 capex revised to Rs 300 crore from Rs 150 crore. Targeting USFDA, EU-GMP and ANVISA approvals for US, EU and SRA markets. Completion targeted for Q2 2028.
Likely market impact
Capex doubled to Rs 300 cr for subsidiary upgrade; targets large biologics CDMO market but revenue flows only from 2028 with execution risk.